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Abstract
Background: Psoriasis is one of the most frequent skin diseases world-wide. The disease impacts enormously on affected
patients and poses a huge financial burden on health care providers. Several lines of evidence suggest that the nuclear
hormone receptor peroxisome proliferator activator (PPAR) b/d, known to regulate epithelial differentiation and wound
healing, contributes to psoriasis pathogenesis. It is unclear, however, whether activation of PPARb/d is sufficient to trigger
psoriasis-like changes in vivo.
Methodology/Principal Findings: Using immunohistochemistry, we define the distribution of PPARb/d in the skin lesions of
psoriasis. By expression profiling, we confirm that PPARb/d is overexpressed in the vast majority of psoriasis patients. We
further establish a transgenic model allowing inducible activation of PPARb/d in murine epidermis mimicking its distribution
in psoriasis lesions. Upon activation of PPARb/d, transgenic mice sustain an inflammatory skin disease strikingly similar to
psoriasis, featuring hyperproliferation of keratinocytes, dendritic cell accumulation, and endothelial activation. Development
of this phenotype requires the activation of the Th17 subset of T cells, shown previously to be central to psoriasis. Moreover,
gene dysregulation in the transgenic mice is highly similar to that in psoriasis. Key transcriptional programs activated in
psoriasis, including IL1-related signalling and cholesterol biosynthesis, are replicated in the mouse model, suggesting that
PPARb/d regulates these transcriptional changes in psoriasis. Finally, we identify phosphorylation of STAT3 as a novel
pathway activated by PPARb/d and show that inhibition of STAT3 phosphorylation blocks disease development.
Conclusions: Activation of PPARb/d in the epidermis is sufficient to trigger inflammatory changes, immune activation, and
signalling, and gene dysregulation characteristic of psoriasis.
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Introduction
Psoriasis is one of the most frequent skin diseases world-wide,
affecting appr. 2% in Caucasian, and 1% in African populations
[1]. The disease represents a life-long affliction of affected patients.
About 60% of psoriasis patients suffer from moderate to severe
disease, i.e. more than 10% of the body surface area is covered by
psoriatic plaques [2]. These patients are largely excluded from
participation in activities involving public skin exposure due to
stigmatization. Moreover, they exhibit increased rates of depres-
sion and alcohol consumption causing secondarily increased
mortality [3,4]. Besides high direct treatment-related costs,
absence from work-related indirect cost is enormous [5] and lack
of employment is attributed to the disease in one-third of psoriasis
patients [6]. Thus, psoriasis does not kill, but it impacts
enormously on those affected and poses a huge financial burden
on health care providers worldwide.
Among psoriasis patients, the prevalence of metabolic syndrome
is increased [7] and an increased body mass index is a strong risk
factor for psoriasis [8]. Although the molecular mechanisms
underlying this association are unknown, it likely involves the
existence of overlapping signalling pathways in psoriasis and other
disorders of metabolism and chronic inflammation. The nuclear
hormone receptor peroxisome proliferator activator (PPAR) b/d
has well established roles both in metabolism and in the skin. On
the one hand, PPARb/d is a key regulator of adipogenesis and
glucose metabolism [9]. On the other hand, it regulates
keratinocyte differentiation [10]. The PPAR subfamily of nuclear
hormone receptors also includes PPARa (target of fibrate class
lipid lowering drugs) and PPARc (target of the rosiglitazone-family
of anti-diabetes drugs), all of which form heterodimers with the
RXRa subunit of retinoid receptors and require binding of ligands
in order to bind cognate promoters and transactivate distinct set of
target genes. All three isoforms have been extensively reviewed
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Several lines of evidence support a role for PPARb/d in psoriasis.
It is upregulated in psoriatic skin [12,13], induced by TNFa
[14,15], stimulates proliferation and blocks apoptosis in keratino-
cytes [16], and induces angiogenesis [17], all of which is consistent
with a disease-promoting role in psoriasis. Thus, induction of
PPARb/d in the context of metabolic dysregulation might
underlie the observed clinical association of psoriasis with
metabolic disease.
PPARb/d represents an isoform of the peroxisome – prolif-
erator activator receptor subfamily of nuclear hormone receptors.
The inflammatory patches of psoriasis exhibit a number of
characteristic properties which are important clues to the
underlying pathogenesis. Macroscopically, they are inducible by
wounding or other mechanical skin trauma, indicating that
challenges to the skin barrier trigger specific response pathways.
Histologically, they are marked by increased keratinocyte
proliferation, as well as a block in terminal differentiation.
Accordingly, markers of late differentiation, including fillagrin,
are decreased [18]. Besides keratinocyte biology, psoriasis is
marked by complex pattern of immune system activation,
including expansion of CD11c
+ dendritic cells [19], upregulation
of interferon signalling, and influx of T cells. Specifically, the Th17
subset of T cells has recently emerged as central for the disease
[20]. In addition, endothelial cells are activated, bactericidal
proteins accumulate, and a variety of soluble mediators are
overexpressed (reviewed in [21]). Finally, the IL12/23p40 gene,
the IL23 receptor, the b-defensin locus, as well as the HLA-C
region harbour genetically predisposing variants [22], suggesting
that quantitative differences in immune response pathways affect
disease penetrance.
The combination of proliferative changes and a distinctive
immune response pattern in psoriasis has long been recognized for
its similarity to the wound response. Thus, like wound response
pathways, the development of inflammatory psoriasis plaques are
triggered by mechanical skin trauma, as well as infection.
Therefore, in many respects psoriasis represents a proliferative
wound response failing to terminate, suggesting the existence of
molecular feed-forward circuits fuelling a vicious circle. In this
regard, too, the upregulation of PPARb/d is notable since it is an
important regulator of the wound response [10].
We report here that PPARb/d activation is sufficient to trigger a
skin disease replicating many elements of psoriasis. Our findings
identify PPARb/d as a molecular link between metabolism,
keratinocyte differentiation, and the epidermal immune response.
Results
Overexpression of PPARb/d in psoriasis
We and others have previously shown that PPARb/d is
overexpressed in psoriasis. In order to independently confirm
those results, we re-analyzed two publicly available large gene
expression datasets, totalling 58 paired lesional and non-lesional
skin samples, for the expression of all PPAR isotypes. As shown in
figure 1a, both data sets confirm highly significant upregulation of
PPARb/d in psoriatic skin whereas both PPARa and PPARc are
downregulated, consistent with the notion that PPARb/d acts
antagonistically to PPARc in psoriasis, as previously proposed
[12]. Furthermore, we localized the site of maximal PPARb/d
accumulation in the skin by immunohistochemistry. As shown in
figure 1b, PPARb/d is found in the cytosol of the lower epidermis
both in normal skin and psoriasis. By contrast, strong nuclear
Figure 1. Overexpression of PPARb/d in psoriasis. A. Fold-change of mRNA expression of PPARb/d (black columns), PPARa (shaded), and PPARc
(white) between lesional and non-lesional skin. Data shown represent mean 6 s.d. from the GAIN dataset (left, n=30) and the GSE14905 dataset
(right, n=28). p,10
23 for all data points shown. For each PPAR isoform, the probe yielding the highest hybridization signal was used to calculate the
data shown (probesets 37152_at, 226978_at, 208510_at, respectively). B. Nuclear accumulation of PPARb/d in suprabasal epidermis in psoriasis skin
lesions. Representative immunohistochemistry of paraffin-embedded lesional (left) and control (middle) skin samples stained with anti-PPARb/d,a s
well as staining control (right). Magnification 2006.
doi:10.1371/journal.pone.0009701.g001
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This pattern was highly reproducible (found in all eight lesional
skin samples examined, figure S1a). These data confirm that
upregulation of PPARb/d is a consistent feature of psoriasis and
define the suprabasal epidermis as major site of its activation.
Targeting PPARb/d expression to suprabasal skin in mice
in vivo
In mice, PPARb/d is not expressed in inter-follicular epidermis
beyond the postnatal period [23]. To model the suprabasal
expression of PPARb/d observed in psoriasis in humans, we
initially intended to target transgenic PPARb/d expression using a
‘‘conventional’’ promoter active in suprabasal epidermis, e.g. the
involucrin promoter. However, a transgenic line expressing
PPARb/d under the control of the rat CYP1A1 promoter was
already available, and turned out to afford skin-specific PPARb/d
activation, as follows. The CYP1A1 promoter allows expression
induced by the aryl hydrocarbon receptor (AhR) [24]. This
promoter activity is mediated by a well-documented so-called
‘‘DXE/XRE’’ sequence cluster conferring responsivity to AhR
[25]. In order to bind to the DXE/XRE cluster, the AhR must first
be ligand-activated, which can be achieved by employing specific
syntheticchemicalssuchasindole-3-carbinole(I3C).However,even
in the absence of AhR activation and binding to the CYP1A1
promoter, a EGFP reporter gene placed under the control of the
CYP1A1 promoter was found to be constitutively and strongly
active in skin-associated sebaceous glands [26]. We were able to
identify a G/C rich enhancer element most likely responsible for
this sebaceous-specific expression, since this element had previously
been shown to direct strong sebacous-gland specific expression in
the keratin 5 promoter [27]. Indeed, a screen of the GEO database
showed this G/C element to be highly conserved in the promoters
of multiple genes belonging to the top 10% of all genes expressed in
sebaceous glands (fig. 2a, bottom). Not surprisingly then, the
CYP1A1 promoter also conferred high constitutive sebaceous-
specific expression of PPARb/d in the absence of AhR activation
(figure 2b). Human, rather than murine PPARb/d, was chosen as
transgene to facilitate subsequent drug screening applications. We
next observed that, unexpectedly, administration of the highly
selective PPARb/d-agonist GW501516 to the chow of PPARb/d-
transgenic mice induced subsequent additional expression of the
PPARb/d-transgene in the epidermis (fig. 2c). Thus, functional
activation of PPARb/d expressed at high level in the sebaceous
glands causes secondary transgene expression in the epidermis.
(RT-PCR analysis of PPARb/d -transgene expression revealed a
borderline-detectable expression in whole-skin samples, consistent
with the sebaceous glands forming a small minority of all skin
associated cells, Figure S8). It is known that ligand-mediated
activation of PPARb/d in the sebaceous gland triggers sebocyte
differentiation [28,29] and delivery of sebum to the skin [30],
containing lipoxygenase-derived bioactive lipids that can bind and
activate the AhR, such as LXA4 or 5,6-DiHETE [31,32]. Once
ligand-bound, the AhR is then able to transactivate the expression
of the CYP1A1-controlled PPARb/d transgene in the epidermis via
the AhR-responsive DXE/XRE element (shown in fig. 2d). In
confirmation of this proposed mechanism, the transcriptional
induction of the CYP1A1-controlled PPARb/d transgene in the
epidermis could be replicated by direct topical cream application of
the AhR ligand indole-3-carbinole (I3C) to the skin (I3C, fig. 2e).
Furthermore, expression of transgenic PPARb/d was epidermis-
specific and was not detectable in dermal fibroblasts, endothelia,
skin – associated T cells, or any other organ screened, including
intestine, muscle, liver, spleen (Fig. S1b), confirming that activation
of AhR only occurred in the skin. Taken together, use of the rat
Cyp1A1-driven expression of PPARb/d and ligand-mediated
activation by the specific PPARb/d agonist GW501516 promoter
affordsatightlycontrolledepidermis-specificinducibleexpressionof
PPARb/d. Although we have not identified the endogenous AhR
ligand(s) mediating secondary induction of the transgene in the
epidermis, the net effect is a distribution and expression level of
PPARb/drathersimilartothatobservedinhumanpsoriasis(fig.2f).
Psoriasis-like skin disease in PPARb/d transgenic mice
As early as seven days after initiation of PPARb/d - activation
by GW501516 (GW), scaling, inflammation, and skin thickening
was notable in all mice (figure 3a–c). Skin roughening (‘‘hyper-
keratosis’’) and concomitant hair loss was maximal in regions
subjected to mechanical friction, such as abdomen (fig. 3b, S2), the
paws (fig. 3a), or the chin (fig. S2). While psoriasis-like plaques also
developed on the back in some mice (fig. 3c), changes on the dorsal
skin were mostly limited to scaling (fig. S2). Thus, the overall
distribution of skin changes suggest that mechanical friction
contributes a trigger effect similar to that characteristic of psoriasis.
Histology showed epidermal thickening (fig. 3e), dilation of dermal
vessels (black arrowhead), and abundant lymphocytes (white
arrowheads). Moreover, Ki67 staining demonstrated massive
hyperproliferation in the basal layer of the epidermis (fig. 3g).
All of these changes are highly similar to those found in psoriasis.
In contrast to psoriasis, the granular layer was prominent (fig. 3f,
white arrowhead), consistent with the known effect of PPARb/d
on epidermal differentiation [33]. In order to exclude that AhR
activation as such contributed to the development of skin disease,
we also administered the AhR ligand I3C in the chow at a very
high concentration (0.5% w/w) in the absence of GW501515
administration, which did not induce a skin phenotype. Likewise,
skin disease could be effectively replicated by topical cream-based,
instead of systemical, application of GW501516 + I3C to the skin,
but not by I3C alone (fig. 3h), consistent with the observation that
I3C induces transcription of the CYP1A1-driven PPARb/d
transgene (fig. 2e), but does not activate it. Finally, C57Bl/6j wild
type mice fed GW501516 did not exhibit skin changes. Thus, the
psoriasis-like skin disease in PPARb/d transgenic mice is triggered
solely by activation of PPARb/d overexpressed in the skin, but not
by endogenous murine PPARb/d.
Immune system activation and involvement of Th17 cells
in PPARb/d dependent skin disease
In order to further explore overlaps of the skin phenotype in
PPARb/d transgenic mice with psoriasis, we next characterized
immunological changes after disease induction. As shown in
figure 4a, there was a massive influx of CD4
+ T cells into the
dermis and, to a lesser extend, of CD8
+ T cells into the epidermis.
CD11c+ dermal dendritic cells were abundant, while CD11c+
epidermal Langerhans cells were not found. Activation of
endothelial cells was also evident by staining with CD31. All of
these changes are highly consistent with those typical of psoriasis.
Co-immunofluorescence studies revealed that the PPARb/d
transgene was not found in either endothelial cells or dermal
dendritic cells (fig. S3), further confirming that the skin disease in
PPARb/d transgenic mice is driven by expression of the transgene
in suprabasal epidermal keratinocytes, but not other cell types.
Th17 cells are required, but not sufficient, for phenotype
development
Since the Th17-subset of T cells is of central importance in the
immune activation of psoriasis, we next quantified these cells using
intracellular FACS analysis. Indeed, Th17-cells, marked by
PPARb/d in Psoriasis
PLoS ONE | www.plosone.org 3 March 2010 | Volume 5 | Issue 3 | e9701expression of IL17, were significantly expanded in the psoriasis-
like plaques of PPARb/d mice, whereas the Th1 subset, marked
by IFNc
+ expression, was not (fig. 4b,c). A small, but statistically
significant expansion of IL17
+ cells was also noted in peripheral
lymphoid organs upon GW501516 stimulation (fig. S4). To assess
the requirement of Th17 cells for PPARb/d - mediated skin
disease, we depleted them in vivo by intraperitoneal injection of
anti-IL12/23p40, analogous to the monoclonal antibody (usteki-
numab) used to treat psoriasis. We extended this experiment to
include the effect of injection using anti-TNFa. Blockade of TNFa
is an established treatment for psoriasis. Since TNFa itself induces
PPARb/d expression [14], blocking of TNFa- should not be able
to completely abrogate skin phenotype development in PPARb/d-
transgenic mice since PPARb/d expression is enforced down-
stream of TNFa in this model. As shown in fig. 4d, treatment with
anti-IL12/23p40, but not with anti-TNFa, effectively suppressed
expansion of Th17 cells in GW501516-treated PPARb/d
transgenic mice, verifying that the treatment had the expected
effect. Strikingly, Th17-depletion caused a significant reduction of
disease severity, as shown in fig. 4e and S5. By contrast, the effect
Figure 2. Inducible expression of PPARb/d in mouse epidermis. A. Cis-regulatory elements in the rat CYP1A1 promoter used to drive
inducible expression of human PPARb/d. Upper panel: Map of the sebaceous – specific G/C-box element and the AHR – responsive DXE/XRE cluster in
the cyp1A1 promoter as well as the human human K5 promoter. Bottom panel: ClustalW alignment of promoters identified by a BLAST search using
the 20 bp G/C element of the Cyp1A1 promoter. All of the genes shown were found in the top 10% percentile of all transcripts expressed in human
sebaceous glands (GDS3215 at the NCBI GEO website www.ncbi.nlm.nih.gov/geo/). B. Immunohistochemistry using anti-PPARb/d of mice transgenic
for human PPARb/d driven by the rat CYP1A promoter (PPARb/d TG), as well as wild type mice. Magnification 2006C. Immunohistochemistry of skin
samples from PPARb/d transgenic mice taken before, or 48 h after after initiation of PPARb/d activation by oral administration of the synthetic ligand
GW501516 in the chow; (inset in ‘‘48 h’’: 4006); d. schematic illustrating the mechanism regulating constitutive expression of transgenic PPARb/d
driven by the rat CYP1A1 promoter in sebaceous glands, as well as delayed PPARb/d expression in the epidermis after ligand-mediated activation of
PPARb/d e. PPARb/d immunohistochemistry 48 h after topical cream application of indole-3-carbinole (I3C) to the skin of PPARb/d transgenic mice at
4006(right) magnification. f. Immunohistochemistry of PPARb/d in the skin of PPARb/d - transgenic mice after seven days of feeding of the PPARb/d
ligand GW501516 in the chow (left) and in human psoriasis skin (right).
doi:10.1371/journal.pone.0009701.g002
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cells are required for full disease expression in PPARb/d
transgenic mice. In order to clarify whether they are sufficient to
trigger disease development, we performed adoptive transfer of
splenocytes from PPARb/d transgenic mice with active disease to
wild-type mice, which had previously been depleted of endogenous
CD4
+ cells. This treatment failed to induce any skin phenotype
even after GW501516 administration to the recipient mice.
Moreover, when GW501516 was administered to naı ¨ve wild type
C57Bl/6j mice, they did exhibit a modest increase of Th17 cells in
peripheral organs (fig. S4), indicating that endogenous murine
PPARb/d also stimulates Th17 cell expansion. Wild type mice did
not, however, develop skin disease. Thus, Th17 cells are required,
but not sufficient for development of psoriasis-like disease in
PPARb/d transgenic mice, although we cannot rule out that their
presence in the skin in high numbers might allow disease
development.
Psoriasis-like gene dysregulation in PPARb/d transgenic
mice
Although psoriasis lesions are complex, involving various cell
types and a multitude of dysregulated genes, the observed changes
in gene expression are remarkably reproducible between different
patients. This is demonstrated by the tight correlation between two
large independent expression profiling datasets (Fig. S6), thus
yielding a consistent psoriasis-specific pattern of global gene
dysregulation. We studied to what extent this pattern is reflected in
PPARb/d mice. As shown in figure 5a, most of the top 50 genes
upregulated in lesional skin of PPARb/d mice were found
congruently upregulated in human psoriasis. Quantitative real-
time-PCR of selected genes confirmed that the changes observed
by microarray-based expression profiling were reproducible (figure
S7). Indeed, 56% of all upregulated and 33% of all downregulated
genes in PPARb/d mice were found congruently regulated in
psoriasis, respectively (figure 5b, clusters I and VI). Conversely,
appr. 30% of all genes dysregulated in human psoriasis were found
to be regulated congruently in PPARb/d mice (table S3). Geneset
Enrichment analysis (GSEA) independently confirmed a highly
significant enrichment of those genes upregulated in psoriasis
(defined as gene-set) in lesional skin of PPARb/d mice (figure 5c).
Only two small subsets of genes (8.3% of all, clusters III and IV)
displayed inverse regulation between psoriasis and PPARb/d
mice. When analysing the functional profile of these, we observed
that cluster III, containing genes upregulated in PPARb/d mice
but downregulated in psoriasis, was enriched for markers of late
epidermal differentiation (e.g. FLG, PCDH21), indicative of cells
in the so-called granular layer, which is prominent in PPARb/d
mice (fig. 3f) but absent in psoriasis. Cluster IV, containing genes
upregulated in psoriasis but downregulated in PPARb/d mice, was
highly enriched for interferon-signalling (fig. 5b, table S3), where
we were able to identify the mechanism underlying this
discrepancy (see below). Taken together, expression profiling
Figure 3. Skin phenotype in PPARb/d TG mice twenty days after GW501516 (GW) administration for twenty days. (a–c) Gross
morphology, (d–e) H&E histology of control mice not treated with GW (d), or fourteen days after induction (e–g). Magnification 2006(d,e) or 4006(f).
The white arrowhead in (f) denotes the granular layer. (g) Immunostaining for Ki67 of skin from PPARb/d TG mice maintained in the absence (left) or
presence (right) of GW. Magnification 2006. (h) Induction of skin disease by topical application of either 0.3% of indole-3-carbinole (I3C, left) or I3C
plus 0.3% GW501516 once daily to shaved abdominal skin. Gross macroscopic phenotype (top) and H&E histology of treated skin (bottom) was
documented 10 days after beginning of treatment.
doi:10.1371/journal.pone.0009701.g003
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PLoS ONE | www.plosone.org 5 March 2010 | Volume 5 | Issue 3 | e9701Figure 4. Immune activation in PPARb/d-mediated skin disease. (a) Immunohistochemistry for CD4, CD8, CD11c, and CD31 (Pecam 31) of skin
from PPARb/d transgenic mice maintained in the absence (top) or presence of GW501516. Magnification 2006, (b) flow cytometry analysis showing
intracellular FACS-staining for IFNc and IL17 of skin cells (gated for CD4) from wild type and PPARb/d transgenic mice maintained in the presence or
absence of GW501516, respectively. Numbers in quadrants indicate frequency of positive cells, (c) frequency of CD4
+IL17
+ of IL17
+ cells (expressed as
percent of all CD4
+ gated cells) in PPARb/d transgenic and C57Bl/6 wild type mice maintained in the presence or absence of GW501516 (n=4 per
group), as determined by flow cytometry. * p,0.01; ** p,0.001, (d) frequency of CD4
+IL17
+ Th17 cells (left y-axis, black columns) and ratio of IL17
+
and IFNc
+ cell frequencies (righ y-axis, grey columns) in the skin of PPARb/d mice maintained in the absence or presence of GW501516 with or
without i.p. injection of anti-TNFa,o raIL12/23p40 (n=4, see Methods), (e) disease severity, expressed as mean 6 s.d., assessed by the degree of
erythema, thickening, scaling, and hair loss (see Methods, representative photographs of mice on day 19 post induction are shown in figure S6) in
PPARb/d transgenic mice GW501516 – containing chow with or without additional intraperitoneal injection of anti-TNFa or aIL12/23p40 (anti-IL12).
*p ,0.01, ** p,0.001 (treatment vs. control).
doi:10.1371/journal.pone.0009701.g004
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PLoS ONE | www.plosone.org 6 March 2010 | Volume 5 | Issue 3 | e9701Figure 5. Congruent gene dysregulation in PPARb/d mice and psoriasis. (a) Fold-change between the lesional skin of PPARb/d mice after
administration of GW501516 and control mice (n=3 per group), and between lesional and non-lesional skin samples from psoriasis obtained through
the GAIN (I) and the GSE14905 (II) datasets, respectively, as detailed in Methods. Red: FC .1.5, Green: FC ,0.8. Shown are the top 50 upregulated
genes. The complete dataset is given in table S1. (b) Heat map showing all genes dysregulated in GW501516-fed PPARb/d mice (n=1077), clustered
PPARb/d in Psoriasis
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the skin disease in PPARb/d mice, strongly suggesting that the
phenotype similarities described above are not a phenocopy but
involve overlapping signalling pathways.
PPARb/d-dependent regulation of specific pathways
When extending analysis of gene expression to functional
processes, we found that processes concordantly regulated in
psoriasis and PPARb/d transgenic mice included lipid-metabo-
lism, differentiation, and proliferation (table S4), which confirmed
the expected, given the known activity profile of PPARb/d.
Likewise, the complete set of genes involved in cholesterol
biosynthesis was strongly co-upregulated (fig. 5d, table S6), as
were a number of proliferation-associated kinases (table S8).
Unexpectedly, however, both the human and the murine datasets
exhibited a highly consistent upregulated IL1-signalling module,
which, remarkably, not only includes pro-inflammatory transcripts
but also the anti-inflammatory components IL1F5, and the IL1-
receptor antagonist (fig. 5e, table S7). Importantly, wild type
C57Bl/6 mice administered GW501516 did not exhibit these
changes (table S1), but did show the expected upregulation of
genes involved in lipid metabolism (table S5), thereby confirming
that the observed induction of IL1-signalling was triggered by the
transgene rather than endogenous murine PPARb/d. These
results strongly suggest that a number of transcriptional programs
known to be dysregulated in psoriasis are regulated by PPARb/d.
Critical role of STAT3 in PPARb/d dependent skin disease
STAT3 is phosphorylated in psoriasis [34], as well as in a
wound-response type model of psoriasis induced by serum
response factor-deficiency [35]. Accordingly, we analyzed STAT3
activation in PPARb/d mice. Tyr-705 phosphorylation of STAT3
was markedly increased in lesional skin of PPARb/d transgenic
mice (figure 6a) and localized to the nuclei of suprabasal cells in
the epidermis (figure 6b). Moreover, inhibition of STAT3
phosphorylation by the JAK2 inhibitor WP1066 led to a marked
attenuation of skin disease, demonstrating the relevance of this
pathway for the development of clinical disease, further demon-
strating the overlap in pathogenesis between psoriasis and the
current model (figure 6c).
STAT3 activation mediates suppression of
interferon-target genes
As described above, the single group of genes upregulated in
psoriasis but downregulated in PPARb/d mice were the interferon
response genes (fig.5b, cluster IV). Strikingly, precisely this set of
genes was previously shown to be repressed by STAT3 in vivo
(fig. 6d, dark shaded columns). We therefore hypothesized that the
notable repression of interferon-response genes in the skin of
PPARb/d transgenic mice with skin disease was mediated by
activation of STAT3. Indeed, repression of STAT3 activation by
use of the JAK2 inhibitor significantly blocked the down-
regulation of one of the most repressed transcripts, IFI27 (fig. 6e).
This STAT3-dependent effect was specific to interferon-response
genes, since the dysregulation of another inflammatory pathway,
exemplified by IL1b, remained unaltered by STAT3 inhibition
(fig. 6e). These data show the inhibition of IFN signalling in
PPARb/d transgenic mice is mediated by STAT3 as part of what
has previously been termed the ‘‘anti-inflammatory response’’
[36].
Discussion
We here show that PPARb/d is activated in the upper
epidermis of human psoriatic skin and that recapitulation of this
event in mice is sufficient to elicit major elements of psoriasis.
PPARb/d transgenic mice exhibit not only down-stream immu-
nological changes but also psoriasis – specific gene dysregulation,
thereby defining subsets of genes regulated by PPARb/d in
psoriasis. Although the current transgenic model exhibits impor-
tant differences to psoriasis (see below) and cannot recapitulate all
features of a polygenetic disease, it does thus indicate that
activation of PPARb/d in the upper spinous layer of the epidermis
initiates a number of inflammatory and immunological changes
seen in psoriasis.
One major implication of the present results is that they suggest
a molecular explanation for the clinical overlap between psoriasis
and metabolic, as well as cardiovascular disease [37]. Thus,
PPARb/d expression is increased in chronic inflammation and
regulated by caloric intake [38,39]. Specifically, factors such as
TNFa which are known to directly induce PPARb/d expression
are increased in the chronic inflammation accompanying
metabolic syndrome [40]. Therefore, obesity, chronic inflamma-
tion, and dyslipidemia may increase the penetrance of psoriasis by
inducing PPARb/d expression. Conversely, it is tempting to
speculate that weight reduction or correction of other PPARb/d -
inducing factors leads to suppression of PPARb/d expression in
the skin, thus dampening disease severity. This may well be a
contributory factor in the clinical observation that the response to
low-dose cyclosporin, an established psoriasis treatment, is
improved in psoriasis patients undergoing weight loss [41].
The role of PPARb/d in inflammation has been extensively and
controversially studied, several papers suggesting anti-inflamma-
tory properties (e.g. [42]), while others find that it stimulates pro-
inflammatory cytokine synthesis including IL-8 and IL1b in
macrophages [43]. Here, we show that, in the skin, PPARb/d
induces a specific IL-1 signalling ‘‘module’’ both in human
psoriasis and in PPARb/d transgenic mice. This module includes
pro-inflammatory mediators such as IL1b, which is known to
stimulate Th17 differentiation [44], and IL1F8, which stimulates
pro-inflammatory mediators in fibroblasts [45], but also anti-
inflammatory cytokines such as IL-1F5, which actually inhibits
inflammatory skin disease [46], as well as the IL1 receptor
antagonist (IL1RA). The latter has recently been shown to be a
direct target of PPARb/d [47] and to be upregulated in psoriasis
[48], thereby corroborating our findings. Thus, the PPARb/d -
mediated induction of IL1-family cytokines in psoriasis defies a
by congruence with psoriasis. Color codes for –fold change are indicated. The genes in all clusters are detailed in table S2. (c) gene-set enrichment
analysis (GSEA), performed using the top 500 genes upregulated in psoriasis lesions from the GSE14905 dataset (top), or the GAIN dataset (bottom),
as genesets, respectively, and the complete mouse array collapsed to single genes as expression dataset. Analysis was run with 100 permutations and
a classic statistic, NES = normalized enrichment score. The blue-red lines on the bottom represent heat-map of human genes found to be
upregulated (blue on top) or downregulated in the mouse set. (d) Induction of cholesterol biosynthesis, conjugation, and channeling by PPARb/d.
Red: upregulated in psoriasis and PPARb/d transgenic mice, blue: upregulated only in PPARb/d transgenic mice. Shaded boxes: repressed by Foxo1.
(e) Induction of IL-1 signalling by PPARb/d. Datasets and color codes are as in (a). ‘‘n.s.’’: p.0.01; ‘‘--’’: fold change between 0.8–1.2., blue print: anti-
inflammatory. * gene located within the IL1 cluster on chr. 2q between 113.2–113.7 Mb. (IL1F7 has only been identified in homo sapiens and bos
taurus, the closest homologue in mice is IL1F5.).
doi:10.1371/journal.pone.0009701.g005
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Clearly, these results would signal some caution regarding the
proposed use of PPARb/d agonists to treat a variety of conditions
[49].
We here identify activation of STAT3 as a novel pathway
targeted by PPARb/d. PPARb/d activation evidently causes
psoriasis-like disease not solely through STAT3 activation since (i)
the phenotype is not completely reversed by inhibition of STAT3
and (ii) overexpression of STAT3 alone causes a less widespread
psoriasis-like phenotype with a much longer latency [34].
Regarding the mechanism of STAT3 activation, STAT3 can be
phosphorylated by a number of kinases. Of these, at least two
appear to be involved. First, the two EGF-family ligands TGFa
and HB-EGF, previously identified as a direct transcriptional
target of PPARb/d [12], are highly upregulated in PPARb/d as
well as in psoriasis, suggesting that EGF-receptor activation
contributes to STAT3 phosphorylation. Second, PTK6 kinase,
which also phosphorylates STAT3 [50], is the most highly
upregulated kinase in psoriasis and PPARb/d mice (table S8).
Thus, at least two kinase pathways converge on STAT3
phosphorylation both in psoriasis and PPARb/d mice.
An obvious difference between the skin disease induced by
activation of PPARb/d and psoriasis in humans is the regulation
of IFN signalling. While IFN response genes are strongly induced
in psoriasis they are repressed in PPARb/d transgenic mice. On
the other hand, subsequent downstream events, including CD4+
and CD8+ T-cell influx, endothelial activation, dendritic cell
accumulation, as well as Th17 activation are all recapitulated
preserved in this model. Therefore, the present data suggest that
upregulation of interferon response genes is not, as commonly
assumed, required for sustained disease. Furthermore, while the
upregulation of IFN response genes could be taken for granted in
the milieu of a wound-response, our data show that they should
actually be repressed by the so-called anti-inflammatory response
mediated by STAT3 [36,51]. Their continuous upregulation
despite STAT3 activation suggests the existence of as yet to be
identified factors actively inhibiting STAT3 repression of IFN
target genes (schematically shown in fig. 6f).
Psoriasis is a genetically determined disease and genomic
variants at the PPARb/d genomic locus have not so far been
associated with psoriasis. Although this might be regarded as
evidence against a role for PPARb/d in psoriasis, our data clearly
show that overexpression of PPARb/d in psoriasis skin lesions is a
common phenomenon occuring in the vast majority of psoriasis
patients (fig. 1). Thus, upregulation of PPARb/d appears to occur
downstream of individually variable genomic risk, offering a
potential target for treatment relevant for most patients.
Apart from interferon response genes, the other major
difference in gene expression between psoriasis and the phenotype
in PPARb/d mice is terminal epidermal differentiation, which is
blocked in psoriasis, but increased in the mouse model, which
confirms the established pro-differentiation activity of PPARb/d
[52] and the fact that it triggers differentiation in wound healing
[28,53]. In psoriasis, on the other hand, late epidermal differenta-
tion is disturbed and the skin barrier disrupted. Based on the data
presented here, one may speculate that the suppression of terminal
differentiation and the block in skin barrier repair, aggravated by
genomic risk alleles such as the recently described LCE3 variant
[54], act as stimuli to maintain sustained upregulation of PPARb/
d in the upper epidermal layers. The net effect would be the
establishment of a vicious cycle, schematically shown in fig.6f,
which is able to account for the chronic persistent course typical of
psoriasis.
In conclusion, we here identify a central role for PPARb/d in
the pathogenesis of psoriasis and identify IL1 and STAT3
signalling as novel pathways regulated by PPARb/d. Our data
suggest novel approaches to psoriasis treatment. Finally, our results
underscore that PPARb/d activation as a treatment strategy for
metabolic diseases might harbour the risk of pro-inflammatory
effects or autoimmune activation.
Methods
Ethics Statement
All work involving animals was approved by the Tayside Ethics
Committee. Storage and use of all tissues included in the work
presented here was approved by the Tayside Committee on
Medical Research Ethics B (REC ref. Nr. 07/S1402/90).
PPARb/d immunohistochemistry
Paraffin-embedded samples were obtained from the Tayside
Tissue bank. Prior to biopsy, patients gave written consent to
storage and analysis of biopsy samples. Sections from paraffin
embedded tissue (nominally 4 microns thick) were cut onto
superfrost plus slides (VWR International Ltd) and dried for
1h r a t 6 0 uC before being de-paraffinised in Histoclear
(National Diagnostics) and then rehydrated through a graded
alcohol series. 10 mM Citric acid buffer, pH 6.0 was used as
standard microwave-based antigen retrieval methods. Sections
were microwaved in a pressure cooker for 15 min before being
immunostained on a DAKO autostainer using VectastainH
ABC kits (Vector Labs) according to the manufacturer’s
protocol. Briefly, sections were blocked in either normal goat,
rabbit or horse serum containing 10%(v/v) from stock avidin
solution (Vector Labs) for 20 min followed by 1 hr incubation
with anti-PPARb/d (R&D, PP-K9436) at 1:100 overnight at
4uC for human samples (incubation for 1 h at room tem-
perature yielded comparable results.), and 1:1000 for mu-
Figure 6. Activation of STAT3 by PPARb/d. (a) Western blot of whole skin samples from two GW501516-treated (GW) and two control PPARb/d
transgenic mice, respectively, probed with anti phospho-STAT3 (top) and anti-STAT3 (bottom) along with anti-GAPDH loading controls (top-band of
the STAT3 doublet represents STAT3a, bottom-band STAT3b, respectively), semi-quantitative densitometry performed using ImageJ is included on
the bottom, (b) immunofluorescence with anti phospho-STAT3 of GW-treated skin (upper left), upper right: same with DAPI counterstain to verify
nuclear localisation, bottom left: control stain performed in the presence of blocking peptide, lower right: PPARb/d transgenic mouse not treated
with GW. White dashed lines mark the dermo-epidermal bounday; all samples at 4006magnification. * = hair shaft (c) H&E histology of skin from
GW-treated (left panel), untreated (middle), GW-treated mice concurrently receiving intraperitoneal injections of the STAT3 inhibitor WP1066 (right)
at 2006magnification, (d) fold change of genes previously shown to be repressed by activated STAT3 (dark grey columns, data taken from [56]) and
their regulation in GW501516-fed vs. control PPARb/d transgenic mice (white), lesional vs. non-lesional skin from psoriasis patients in the GSE14905
(black), as well as the GAIN (light grey) datasets, respectively. * denotes genes that are not contained in cluster IV (table S2) since they did not meet
the p,0.01 cut-off. (e) Taqman-based qPCR of IFI27 and IL1b from whole skin of untreated (black columns), GW-fed (white), and GW-fed + WP1066-
injected PPARb/d mice (grey), respectively (n=3 mice per group), * p,0.05; (f) schematic illustrating the PPARb/d /STAT3 /IL-1 pathway identified
here, the role of PPARb/d in maintaining chronically active psoriasis, as well as disease-enhancing role of predisposing genomic risk alleles. The box
on the upper left lists factors known to trigger both PPARb/d induction as well as clinical psoriasis flares.
doi:10.1371/journal.pone.0009701.g006
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pH 7.6, followed by anti-mouse-biotin, antibody for 30 min
followed by Vectastain Elite ABC reagent for another 30 min.
Liquid Diaminobenzidine (DAB) (DAKO) was applied for
5 min and sections were counterstained with Mayer’s haema-
toxylin.
H&E histology
Paraffin-embedded samples were heated for 15 minutes.
Samples were treated with 3 washes of Xylene, followed by a
series of graded alcohol washes. Samples were washed with water
followed with staining with Harris’ Haematoxylin. Wash 2 with
water. Samples incubated in 0.1% acid alcohol for 1 minute
followed by a 3
rd wash with water. Samples were then incubated in
STWS for 1 minute followed by a 4
th wash with water. Samples
stained with Shandon Eosin for 30 seconds followed by a 5
th wash.
Samples were re-hydrated with a series of graded alcohol washes
followed by 3 washes with Xylene. Sections were mounted with
DPX.
Generation of PPARb/d transgenic mice
PPARb/d transgenic mice were generated by cloning full-length
human PPARd downstream of the human CYP1A1 promoter.
Plasmids encoding human PPARd were prepared as follows. The
PPARd coding sequence was amplified using primers PRMG15
(59-CTAGTCTAGAATGGAGCAGCCACAGGAGGAAGC-39)
and PRMG3 (59-CTAGTCTAGATTAGTACATGTCCTTG-
TAGATCTCCTG-39), respectively (XbaI-sites underlined, ATG
start codon in bold). PCR products were cleaved with XbaI and
cloned in plasmid pUHD10-3 (M. Gossen, unpublished, Genbank
accession number U89931) creating pMGD7 (PPARd). The
integrity of the inserts was confirmed by sequencing and cleaved
out using BamHI and ligated into plasmid pAHIR1-b-gal (Camp-
bell, 1996} cleaved with BglII, resulting in the plasmid pMGD72
(PPARd). Proper insert orientation was confirmed by restriction
endonuclease analysis and sequencing. Transgenic mice were
generated by microinjection of the expression unit (NotI fragment)
of the plasmid pMGD72 into pro-nuclei of C57BL/J6 x CBA F1
fertilized eggs. Mice were maintained under standard animal
house conditions.
Disease induction
PPARb/d mediated skin disease was induced either by
administration of powdered standard RMI-chow containing
0.003% GW501516 (w/w, custom – synthesized by AF-Pharma-
ceuticals, UK, to $98% purity), or topical application of 0.3% (w/
w) GW501516 in 10% (w/w) DMSO in Hydromol ointment
(Alliance, UK); for topical induction, control mice received 10%
DMSO in Hydromol.
Flow cytometry and intracellular measurement of IL17
Skin samples were shaved, trimmed of associated fat, cut to
appr. 10–15 mm
3 size using a scissor, incubated in 2 mg/ml
collagenase IV (Roche, cat-nr. 110880855001), 1.1 U/ml dispase I
(Roche, cat-nr. 04942086001) in HBSS for 309 at 37uC.
Subsequently, samples were incubated in RPMI incl. Pen/Strep
and 10% FCS, 0.5 mg/ml PMA, 0.5 mg/ml ionomycin for 3 h.
For the last hour, Brefeldin A was added at 2 mg/ml. Surface and
intracellular staining for CD4-FITC (Pharmingen, clone RM4-4),
CD8-PerCP/Cy5.5b (Pharmingen, 53–6.7), IFNc-APC (Pharmin-
gen, cat-nr. 554413), and IL17-PE (Pharmingen, cat-nr. 559502)
and analysis on a FACS-Calibur was done according to standard
procedures.
TNFa and IL-12 antibody treatment
70 mg of anti-TNFa (Millipore, cat-nr 05-168), anti-IL12/
23p40 (BioLegend, Clone C17.8, cat-nr. 505304), or PBS,
respectively, were injected on three times per week, beginning
on day 1 of GW501516 administration. Mice were sacrificed on
day 22 for tissue analysis. For disease severity, erythema, scaling,
palpable hyperkeratosis, and hair loss were scored as absent (0),
weak (1), moderate (2), or severe (3), respectively, and the sum
calculated for index regions (chin, forepaws, abdomen) chosen in
order to allow hand-held analysis of mice during on-going
treatment.
Expression profiling was performed as detailed in the supporting
information (Method S1).
Western blot STAT3, P-STAT3
Nuclear extracts were made using the NE-PER kit (Pierce).
Protein concentration was determined by Bradford assay. 40 mgo f
protein loaded per well, subjected to SDS-PAGE gel and
transferred to nitrocellulose membrane. Primary antibodies:
1:1000 dilution of Phospho-Stat3 (Tyr705) Antibody (New
England BioLabs UK, 9131S) and 1:1000 dilution of anti-Stat3
(New England BioLabs UK, 9132) followed by HRP– conjugated
anti-rabbit Ig, ECL Plus (GE Healthcare, Amersham), and
detection using a CCD camera.
Immunofluorescence P-STAT3
5 mm thick sections of snap-frozen skin were fixed in methanol,
followed by incubation with anti-Phospho-Stat3 (Tyr705) (D3A7)
(New England Biolabs UK, 9145S) with or without blocking
peptide (New England Biolabs UK, 1195) for 1 hour at RT.
Secondary antibody was Alexa FluroH 488 donkey anti-rabbit IgG
(H+L) (Invitrogen). Coverslips were mounted using ProLongH
Gold antifade reagent with DAPI (Invitrogen, Cat.no.: P-36931).
Treatment with WP1066
WP1066 (Calbiochem, order-nr 573097) was dissolved in
DMSO/PEG 600 (20/80) according to [55] at 1.25 mg/ml. Mice
were injected with WP1066 or vehicle at 75 ml intraperitoneally
three times a week.
Supporting Information
Table S1 Synopsis of dysregulated genes in PPARb/d trans-
genic mice and psoriasis. Sheet ‘‘Changed in PPARd mice’’: all
genes found dysregulated in PPARd mice, as detailed in the file
Method S1. Sheet ‘‘PPARd mice vs psoriasis’’: all genes
dysregulated in PPARb/d mice (orange shaded cells) that are also
present on the two gene expression sets representing psoriasis
(green shaded cells). FC = fold change lesional vs. non-lesional
(psoriasis), or induced vs. non-induced (PPARb/d transgenic
mice).
Found at: doi:10.1371/journal.pone.0009701.s001 (0.65 MB
XLS)
Table S2 Clustering of genes dysregulated in PPARb/d
transgenic mice. The table contains all 1077 genes listed in the
synopsis between dysregulated genes in PPARb/d transgenic mice
and psoriasis, color-coded as up- (red/orange) or down- regulated
(light-green/dark green), as shown in Figure 5b.
Found at: doi:10.1371/journal.pone.0009701.s002 (0.17 MB
XLS)
Table S3 Concordance of gene dysregulation between psoriasis
and PPARb/d transgenic mice.
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DOC)
Table S4 Genes concordantly regulated between PPARb/d
transgenic mice and psoriasis, listed for the functional categories
lipid-metabolism, differentiation, and cell-cycle.
Found at: doi:10.1371/journal.pone.0009701.s004 (0.23 MB
DOC)
Table S5 Genes induced by the PPARb/d agonist GW501516
in the skin of C57Bl/6 wild type mice.
Found at: doi:10.1371/journal.pone.0009701.s005 (0.06 MB
DOC)
Table S6 Expression of genes involved in cholesterol biosynthe-
sis in PPARb/d transgenic mice and psoriasis.
Found at: doi:10.1371/journal.pone.0009701.s006 (0.07 MB
DOC)
Table S7 Interleukin-1 related genes in PPARb/d transgenic
mice and psoriasis.
Found at: doi:10.1371/journal.pone.0009701.s007 (0.09 MB
DOC)
Table S8 Expression of kinase genes in PPARb/d transgenic
mice and psoriasis.
Found at: doi:10.1371/journal.pone.0009701.s008 (0.04 MB
PDF)
Table S9 PPAR isoforms and ligands.
Found at: doi:10.1371/journal.pone.0009701.s009 (0.06 MB
DOC)
Method S1 Expression profiling.
Found at: doi:10.1371/journal.pone.0009701.s010 (0.80 MB
DOC)
Figure S1 (a) Immunohistochemistry of PPARb/d in a panel of
eight paraffin-embedded samples from psoriasis skin lesions,
counterstained with hematoxilin. The inset in the right upper
panel in addition demonstrates expression in dermal fibroblasts
and endothelial cells. Magnification 2006 in each case. (b)
Immunohistochemistry of PPARb/d in PPARb/d- transgenic
mice treated with GW501516 for seven days, counterstained with
hematoxilin. Panels in lower row were taken fom slides stained
with secondary antibody only. Magnification 2006for all panels.
Found at: doi:10.1371/journal.pone.0009701.s011 (3.17 MB TIF)
Figure S2 Macroscopic changes in PPARb/d transgenic mice
upon ligand-mediated activation of PPARb/d by administration of
the ligand GW501516 in the chow. Pictures shown were taken 14
(left) or 20 days (middle, right) after disease induction. Note the
sharp demarcation of hyperkeratosis on the abdomen (middle).
Panel on upper right represents illustrates the scalp, exhibiting
heavy scaling, but no marked erythema.
Found at: doi:10.1371/journal.pone.0009701.s012 (1.79 MB TIF)
Figure S3 Confinement of PPARb/d transgene expression to
suprabasal epidermal keratinocytes. Co-immunofluorescence with
anti-PPARb/d visualized with Alexa288 and either CD11c,
visualized with TexasRed, was performed as described in
Methods. The white dashed line indicates the dermo-epidermal
boundary. Magnification 4006.
Found at: doi:10.1371/journal.pone.0009701.s013 (1.93 MB TIF)
Figure S4 Expansion of Th17 cells upon activation of PPARb/
d. PPARb/d transgenic mice were maintained in the presence
(black columns) or absence (dark shaded) of GW501516, as were
C57Bl6/j wild type (light shaded: GW; white: control) and Th17
cell frequencies determined by intracellular FACS, as described in
Methods. Data show mean 6 s.d. of Th17 cells (top), as well as the
ratio between IL17
+ and IFNc
+ cells (bottom) in the lymphocyte
gate for n=3 mice per group. * p,0.05.
Found at: doi:10.1371/journal.pone.0009701.s014 (0.21 MB TIF)
Figure S5 Inhibition of PPARb/d-mediated skin disease by
depletionof Th17 cells. PPARb/d transgenicmicewere maintained
in the absence (control) or presence (all other groups) of GW501516
and additionally treated by injection of either anti-IL12/23p40, or
anti-TNFa, as described in Methods. Pictures shown were taken
nineteen days after disease induction. Mice were manually
restrained to allow for comparable positioning during photography,
thereby causing artificial tightening of abdominal skin.
Found at: doi:10.1371/journal.pone.0009701.s015 (5.20 MB TIF)
Figure S6 Reproducibility of gene dysregulation in psoriasis.
Fold-change of gene expression between lesional and non-lesional
skin in two independent datasets. The left panel shows all genes,
the right panel all genes significantly upregulated (p,0.001) in
both datasets. R2=0.93 for both panels. The dashed line indicates
theoretically equal up-regulation in the two datasets. Both datasets
were obtained using the same platform (using the Affymetrix
HU133 Plus 2.0 array). The dataset from the GAIN cohort was
obtained from the dbGaP website (www.ncbi.nlm.nih.gov/sites/
entrez?db=gap). The CEL files are also available at the GEO
website of NCBI (GEO dataset GSE13355). In the initial release,
whole-skin expression profiles from paired lesional/non-lesional
samples of 31 psoriasis patients were available which was used for
the present analysis. The CEL files containing the dataset
GSE14905 (n=28 patients) were also downloaded from the
GEO website. The data show the extend of reproducibility of gene
dysregulation across patients and also indicate that -fold changes
obtained with the GSE14905 dataset are consistently slightly
higher than those observed in the GAIN data.
Found at: doi:10.1371/journal.pone.0009701.s016 (0.15 MB
DOC)
Figure S7 Upregulation of psoriasis-associated genes in lesional
skin of PPARb/d transgenic mice. The expression level for the
representative genes shown, previously found to be upregulated in
the skin of PPARb/d mice treated with GW501516 by microarray-
based expression profiling (see main text), was quantified using
TaqMan-based real-time PCR using Assays-on-Demand kits ob-
tained from ABI according to the manufacturer’s instruction
(LCE3f: Mm02605425, Il1b: Mm01336189, Hb-EGF: Mm004-
39305, CRABPII: Mm00801693, ALOX12b: Mm00507782, m1:
MM00436999, ATP12a: Mm00446786). The data shown represent
mean 6 s.d. of GAPDH-calibrated expression levels obtained from
n=3 mice for each group (GW-fed, red columns, vs. control, blue
columns). For all genes, p,0.001 in a two-sided independent t-test.
Found at: doi:10.1371/journal.pone.0009701.s017 (0.09 MB TIF)
Figure S8 Expression of transgenically overexpressed PPARb/d
in murine skin. Whole skin samples from C57Bl/6j wild type (WT)
or PPARb/d transgenic mice fed control chow (Tg) or
GW501516-containing chow (TG+GW) were taken, genomic
DNA digested, and total RNA isolated, followed by cDNA
synthesis. RT-PCR was performed for the indicated number of
cycles using primers specific for the transgene. Two mice for each
condition were used.
Found at: doi:10.1371/journal.pone.0009701.s018 (0.25 MB TIF)
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